MaxCyte, Inc. Notice of Results (7185C)
February 24 2022 - 8:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7185C
MaxCyte, Inc.
24 February 2022
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial
Results on March 22, 2022
GAITHERSBURG, MD, February 24, 2022 - MaxCyte, Inc., (NASDAQ:
MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization,
today announced that it will release financial results for the
fourth quarter and full year of 2021 after the U.S. market close on
Tuesday, March 22(nd) , 2022. Company management will host a
conference call to discuss financial results at 4:30 p.m. Eastern
Time.
Conference Call Details
Interested parties may access the live teleconference by dialing
(844) 679-0933 for domestic callers, (918) 922-6914 for
international callers, for 0203 1070 289 U.K domestic callers, or
for 0800 0288 438 U.K. international callers followed by Conference
ID: 2675034. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/ .
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORTIMMTMTTTBBT
(END) Dow Jones Newswires
February 24, 2022 08:00 ET (13:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024